Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05482126 · ClinicalTrials.gov registry record
Sensory Filtering in the Human Basal Ganglia as a Mechanism of Parkinson's Disease
A clinical trial of Parkinson Disease, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT05482126: Recruiting study of Parkinson Disease, sponsored by University of Alabama at Birmingham.
NCT05482126 is a study of Parkinson Disease that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 30 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05482126, a study of Parkinson Disease, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators are investigating the brain activity associated with sensory information in movement disorders in order to improve treatment of these symptoms beyond what is currently available.
Primary Outcome
Arm movements (hand position, velocity) recorded following stimulus onset, measured by joystick outputs.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Intraoperative Behavioral Testing
- DIAGNOSTIC_TEST Behavioral Testing
Study Locations (1)
Alabama
- The University of Alabama at Birmingham Hospital - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-06-08 |
| Est. Completion | 2026-12-31 |
What NCT05482126 shows while recruiting
NCT05482126 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which Intraoperative Behavioral Testing is the first listed.
NCT05482126 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT05482126 about?
NCT05482126 is a clinical study titled "Sensory Filtering in the Human Basal Ganglia as a Mechanism of Parkinson's Disease". The investigators are investigating the brain activity associated with sensory information in movement disorders in order to improve treatment of these symptoms beyond what is currently available.
What is the current status of trial NCT05482126?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2022-06-08. Estimated completion is 2026-12-31.
What conditions does trial NCT05482126 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT05482126?
The interventions under investigation include: Intraoperative Behavioral Testing (DIAGNOSTIC_TEST), Behavioral Testing (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05482126?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05482126 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05482126's enrollment target sits among peer trials
30 209th of 297 higher than 80 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
RECRUITING · NA
-
Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis
RECRUITING
-
University of Delaware Parkinson's Disease Registry
RECRUITING
-
Neocortical Microarchitecture of Executive Function
RECRUITING · NA
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI